BR0314577A - Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) - Google Patents

Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)

Info

Publication number
BR0314577A
BR0314577A BR0314577-8A BR0314577A BR0314577A BR 0314577 A BR0314577 A BR 0314577A BR 0314577 A BR0314577 A BR 0314577A BR 0314577 A BR0314577 A BR 0314577A
Authority
BR
Brazil
Prior art keywords
tgf
growth factor
inhibitors
triazole derivatives
transforming growth
Prior art date
Application number
BR0314577-8A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0314577A publication Critical patent/BR0314577A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE TRIAZOL COMO INIBIDORES DO FATOR DE CRESCIMENTO DE TRANSFORMAçãO (TGF)". A presente invenção refere-se a derivados novos de triazol da fórmula (Ia-c), intermediários para a sua preparação, composições farmacêuticas contendo-os e até o seu uso medicinal que estão descritos. Os compostos da presente invenção são inibidores potentes da via de sinalização do fator de crescimento transformante ('TGF'-<225>). São úteis no tratamento de vários estados de doença relacionados com TGF incluindo, por exemplo, câncer e doenças fibróticas.
BR0314577-8A 2002-09-18 2003-09-08 Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) BR0314577A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41207902P 2002-09-18 2002-09-18
US48453503P 2003-07-02 2003-07-02
PCT/IB2003/003825 WO2004026307A1 (en) 2002-09-18 2003-09-08 Triazole derivatives as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
BR0314577A true BR0314577A (pt) 2005-08-09

Family

ID=32033582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314577-8A BR0314577A (pt) 2002-09-18 2003-09-08 Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)

Country Status (25)

Country Link
US (2) US7053095B2 (pt)
EP (1) EP1542685A1 (pt)
JP (1) JP2006502236A (pt)
KR (1) KR20050057393A (pt)
CN (1) CN1681502A (pt)
AP (1) AP2005003260A0 (pt)
AR (1) AR041276A1 (pt)
AU (1) AU2003260810A1 (pt)
BR (1) BR0314577A (pt)
CA (1) CA2497971A1 (pt)
CO (1) CO5540390A2 (pt)
EA (1) EA200500376A1 (pt)
EC (1) ECSP055681A (pt)
HR (1) HRP20050251A2 (pt)
IS (1) IS7713A (pt)
MA (1) MA27442A1 (pt)
MX (1) MXPA05002982A (pt)
NO (1) NO20051010L (pt)
OA (1) OA12927A (pt)
PA (1) PA8583401A1 (pt)
PE (1) PE20050074A1 (pt)
PL (1) PL375974A1 (pt)
TW (1) TW200412346A (pt)
UY (1) UY27981A1 (pt)
WO (1) WO2004026307A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
JP4518956B2 (ja) 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク トランスフォーミング成長因子（ｔｇｆ）阻害剤としての新規トリアゾールおよびオキサゾール化合物
AP2005003263A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Pyrazole derivatives as transforming growth factor(TGF) inhibitors.
JP4547271B2 (ja) * 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
KR100910333B1 (ko) 2005-02-23 2009-07-31 시오노기세이야쿠가부시키가이샤 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체
EP1919881B1 (en) 2005-07-25 2013-04-10 Synta Pharmaceuticals Corp. 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders
CA2629432A1 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
EP3685855B1 (en) 2012-10-05 2023-11-22 Kadmon Corporation, LLC Human anti-vegfr-2/kdr antibodies
EP3702443B1 (en) 2013-03-14 2022-01-19 The Brigham and Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
ES2801380T3 (es) 2015-03-04 2021-01-11 Gilead Sciences Inc Compuestos de 4,6-diamino-pirido [3,2-d] pirimidina y su utilización como moduladores de receptor de tipo toll
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3827010A4 (en) 2018-07-23 2022-03-16 Brise Pharmaceuticals Co., Ltd. BISPHOSPHONATE-DRUG CONJUGATES
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物
JPS6025142A (ja) 1983-07-21 1985-02-07 Matsushita Electric Ind Co Ltd 表示装置の電極製造方法
DE3486009T2 (de) * 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
GB9201692D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
AU755498B2 (en) 1997-05-22 2002-12-12 G.D. Searle & Co. 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1999021555A2 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
ES2187473T3 (es) 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
JP2000302680A (ja) * 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040097502A1 (en) 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521915A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
US20040077697A1 (en) * 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP1539748A1 (en) 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors

Also Published As

Publication number Publication date
CO5540390A2 (es) 2005-07-29
CN1681502A (zh) 2005-10-12
KR20050057393A (ko) 2005-06-16
WO2004026307A1 (en) 2004-04-01
AP2005003260A0 (en) 2005-03-31
MXPA05002982A (es) 2005-06-22
NO20051010L (no) 2005-05-31
HRP20050251A2 (en) 2005-10-31
CA2497971A1 (en) 2004-04-01
ECSP055681A (es) 2005-05-30
AR041276A1 (es) 2005-05-11
UY27981A1 (es) 2004-04-30
OA12927A (en) 2006-10-13
IS7713A (is) 2005-02-24
AU2003260810A1 (en) 2004-04-08
EA200500376A1 (ru) 2005-08-25
TW200412346A (en) 2004-07-16
US20040110798A1 (en) 2004-06-10
PE20050074A1 (es) 2005-03-21
EP1542685A1 (en) 2005-06-22
PA8583401A1 (es) 2004-04-23
PL375974A1 (en) 2005-12-12
JP2006502236A (ja) 2006-01-19
US20060128761A1 (en) 2006-06-15
MA27442A1 (fr) 2005-07-01
US7053095B2 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
BR0314577A (pt) Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)
BR0314372A (pt) Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
BR0314302A (pt) Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
BR0314383A (pt) Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
BR0314286A (pt) Compostos de isotiazol e isoxazol como inibidores do fator de crescimento transformante (tgf)
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
BRPI0409109A (pt) novos compostos
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0206955A (pt) Ligantes de receptores de canabinóides
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
SE0103836D0 (sv) Novel compounds
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
GB0112348D0 (en) Compounds
BRPI0407055A (pt) Derivados de isotiazol
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
NZ516506A (en) Interleukin-5 inhibiting 6-azauracil derivatives
EP0227241A3 (en) Medicinal indole and indazole keto sulphone derivatives
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.